Cingulate CING
NASDAQ CING
$5.20 -0.03 (-0.67%)
As of: Sep 22, 2026 · 10:24 AM EDT

Cingulate (CING) Net Income towards Common Stockholders (2021 - 2026)

Cingulate's (CING) quarterly Net Income towards Common Stockholders came in at -$5.9 million in Q2 2026, down 17.8% on a YoY basis from -$7.1 million in Q2 2025, and down 18.49% quarter-over-quarter from -$5.0 million in Q4 2025.

Analysis

Cingulate (CING) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Cingulate (CING) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$5.9 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 17.8% year-over-year to -$5.9 million; the trailing twelve-month figure through Jun 2026 stood at -$21.6 million (down 33.63% YoY), and the FY2025 full-year result was -$17.7 million, down 35.57% from the prior year.
  • Net Income towards Common Stockholders slipped to -$5.9 million in Q2 2026 per CING's latest filing, from -$5.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$2.4 million in Q1 2024 and bottomed at -$5.9 million in Q2 2026.
  • Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$4.0 million in 2022.
  • The widest YoY moves for Net Income towards Common Stockholders: up 79.19% in 2022, down 197.16% in 2022.
  • Over 5 years, Net Income towards Common Stockholders stood at -$3.6 million in 2022, then tumbled by 51.22% to -$5.5 million in 2023, then grew by 10.24% to -$4.9 million in 2024, then slipped by 0.64% to -$5.0 million in 2025, then decreased by 18.49% to -$5.9 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$5.9 million, -$5.0 million, and -$5.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn 5.53 Bn
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 3.62 Bn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn 3.26 Bn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn -238.00 Mn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn 3.32 Bn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 398.69 Mn
8 Revolution Medicines 40.91 Bn 40.91 Bn - -644.37 Mn
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn 237.01 Mn
10 Cingulate 72.81 Mn 72.81 Mn - -5.87 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -5.87 Mn
Dec 31, 2025 -4.95 Mn
Sep 30, 2025 -5.80 Mn
Jun 30, 2025 -4.98 Mn
Mar 31, 2025 -3.00 Mn
Dec 31, 2024 -4.92 Mn
Sep 30, 2024 -3.26 Mn
Jun 30, 2024 -2.50 Mn
Mar 31, 2024 -2.38 Mn
Dec 31, 2023 -5.48 Mn
Sep 30, 2023 -4.72 Mn
Jun 30, 2023 -5.23 Mn
Mar 31, 2023 -3.16 Mn
Dec 31, 2022 -3.63 Mn
Sep 30, 2022 -3.18 Mn
Jun 30, 2022 -3.19 Mn
Mar 31, 2022 -3.96 Mn
Dec 31, 2021 -2.65 Mn
Sep 30, 2021 -15.29 Mn
Jun 30, 2021 -1.43 Mn
API Access

Cingulate Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=CING&period=max&api_key=YOUR_API_KEY